Drug efficacy may be improved by lowering eATP concentrations, ATP synthesis-inhibitor, or preventing ATP internalization via diminishing purinergic receptor activation, causing tumor cells to stop growing and cell death (51). This evidence concerns the gene P2RX1 and neoplasm.